Paul Berger, DO
Pulmonary Disease · Clinton Township, MINPI 1699921163
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 49.4% of the total. Reporting peaked in 2024 at $11,643 and has fallen 75.4% since, to $2,868 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $188.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$11K
- Medical Device Business Services, Inc.$7K
- Pulmonx Corporation$1K
- Intuitive Surgical$994
- United Therapeutics Corporation$140
- Amgen$138
- plus $864 from 17 others
Across 10 payments — averaging $12,256 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$43K
- Regeneron$43K
- Omeros Corporation$23K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Genentech, Inc.$14
What the payments were for
- Consulting fees$10,61449%
- Travel & lodging$6,17929%
- Food & beverage$4,64122%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 50 | $10,606 |
| Medical Device Business Services, Inc. | 8 | $7,227 |
| Pulmonx Corporation | 9 | $1,499 |
| Intuitive Surgical | 7 | $994 |
| United Therapeutics Corporation | 2 | $140 |
| Amgen | 2 | $138 |
| Sanofi | 3 | $104 |
| Boehringer Ingelheim | 6 | $103 |
| AstraZeneca | 6 | $96 |
| Siemens Medical Solutions USA, Inc. | 1 | $91 |
| Mauna Kea Technologies, Inc. | 1 | $84 |
| Inspire Medical Systems, Inc. | 3 | $84 |
| Grifols USA, LLC | 2 | $54 |
| GSK | 3 | $46 |
| Merck | 3 | $36 |
| Viatris Specialty LLC | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Harmony Biosciences LLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,468 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 20 | $527,527 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,404 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,520 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $46 | $12,40412 claims |
| Boehringer IngelheimSpiriva Respimat | $103 | $6,52013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Clinton Township
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.